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AbstrAct
Background Pharmacists’ completion of medication 
reconciliation in the community after hospital discharge 
is intended to reduce harm due to prescribed or 
omitted medication and increase healthcare efficiency, 
but the effectiveness of this approach is not clear. 
We systematically review the literature to evaluate 
intervention effectiveness in terms of discrepancy 
identification and resolution, clinical relevance of resolved 
discrepancies and healthcare utilisation, including 
readmission rates, emergency department attendance 
and primary care workload.
Methods This is a systematic literature review and 
meta-analysis of extracted data. Medline, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), 
EMBASE, Allied and Complementary Medicine Database 
(AMED),Education Resources Information Center (ERIC), 
Scopus, NHS Evidence and the Cochrane databases were 
searched using a combination of medical subject heading 
terms and free-text search terms. Controlled studies 
evaluating pharmacist-led medication reconciliation in the 
community after hospital discharge were included. Study 
quality was appraised using the Critical Appraisal Skills 
Programme. Evidence was assessed through meta-analysis 
of readmission rates. Discrepancy identification rates, 
emergency department attendance and primary care 
workload were assessed narratively.
Results Fourteen studies were included, comprising five 
randomised controlled trials, six cohort studies and three 
pre–post intervention studies. Twelve studies had a moderate 
or high risk of bias. Increased identification and resolution 
of discrepancies was demonstrated in the four studies 
where this was evaluated. Reduction in clinically relevant 
discrepancies was reported in two studies. Meta-analysis did 
not demonstrate a significant reduction in readmission rate. 
There was no consistent evidence of reduction in emergency 
department attendance or primary care workload.
Conclusions Pharmacists can identify and resolve 
discrepancies when completing medication reconciliation 
after hospital discharge, but patient outcome or care 
workload improvements were not consistently seen. 
Future research should examine the clinical relevance of 
discrepancies and potential benefits on reducing healthcare 
team workload.
bAckground
There is growing policy interest in 
improving the safety of transition between 
different health service locations or 
settings.1–4 Transitions include admission 
to hospital from the community, transfers 
within secondary care and discharge back 
to the community. Safe transitions often 
require coordinating care with health-
care professionals in both primary and 
secondary care and providing patients 
with accessible information on post-tran-
sition care.5 One area where these actions 
are crucial is in communicating medica-
tion information. Harm from prescribed 
or omitted medications is higher after 
discharge, and effective medication 
reconciliation has been promoted as one 
way to improve safety.1–4 6–8 Multiple 
definitions of medication reconciliation 
exist, but all involve defining the list of 
medications the patient should be taking, 
altering records to reflect changes and 
ensuring patients and/or carers are aware 
of the changes.1–3 9 
At the transition from hospital to 
community, medication reconciliation is 
necessary for hospital-initiated medication 
changes to be maintained. The medication 
taken by patients in the community, and 
prescribed by their general practitioner 
or primary care physician (from now on 
both termed GP), is often changed during 
hospital admissions.10 On discharge, a 
document is sent to the patient’s GP, and 
sometimes their community pharmacist, 
detailing medication regimen changes 
implemented during their inpatient stay. 
Medication reconciliation ensures the list 
held by the GP or community pharma-
cist (preadmission medication) is updated 
to reflect hospital-initiated changes. 
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Following this process, discrepancies that exist between 
the primary care list of medications and the discharge 
medication list are either intentional discrepancies (a 
conscious decision has been made not to implement 
changes) or unintentional.
From the perspective of the UK, models for providing 
primary healthcare are changing. As in many sectors of 
healthcare, the roles of pharmacists (and other health 
professionals) are being extended.11 Completion of 
medication reconciliation by community pharmacists 
(whose traditional role is medication dispensing) and 
primary care pharmacists (employed by primary care 
organisations) has been prioritised.12 13 It is assumed 
this will increase the safety of care after discharge, 
improve outcomes such as readmission rate and have 
workload benefits by freeing clinical time for GPs. 
While in secondary care improvements in patient 
outcomes of this type of intervention have been 
reported, effectiveness in the community has not been 
established.7 A previous systematic review that exam-
ined all interventions to improve medication reconcili-
ation in primary care found two studies that evaluated 
medication reconciliation after hospital discharge by 
pharmacists.14 These were of low quality and evidence 
of benefit was not found. A further systematic review 
evaluated all interventions (including medication 
reconciliation) undertaken by pharmacists in the 
community after hospital discharge.15 This showed 
that pharmacists can identify potential drug-related 
problems, but the impact on outcomes, such as health-
care utilisation, was inconsistent.
We aimed to focus, in depth, on medication recon-
ciliation performed by community and primary care 
pharmacists after hospital discharge, by systematically 
reviewing published studies that compared this process 
with usual care. The aim was to determine the effec-
tiveness of this intervention on overall discrepancy 
identification and resolution, the clinical relevance 
of resolved discrepancies and healthcare utilisation 
in terms of readmission rates, emergency department 
attendance and primary care workload.
Methods
The study was conducted using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) group guidelines.16 The completed PRISMA 
checklist is included as an online supplementary file
Scope of the review
Studies were included that compared community and 
primary care-based pharmacist-led medication recon-
ciliation with usual practice. We defined medication 
reconciliation as the reconciliation of preadmission 
and postadmission lists of medication. Many studies 
evaluated interventions that included medication 
reconciliation combined with other actions. Studies 
where drug-related problems (such as drug interac-
tions) were identified and corrected were included,17 
but studies focused on medication review (eg, recom-
mendations to optimise medication regimens) were 
not.18 Randomised controlled trials (RCTs), cohort 
studies and pre–post intervention studies were 
included.
Information sources
We searched the Medline (Ovid), Cumulative Index 
to Nursing and Allied Health Literature (CINAHL) 
(EBSCOhost), EMBASE (Ovid), Allied and Comple-
mentary Medicine Database (AMED) (Ovid), Educa-
tion Resources Information Center (ERIC) (Ovid), 
NHS Evidence, Cochrane electronic databases and 
Scopus databases from inception until 1 September 
2017. The reference lists of selected studies were 
hand-searched to identify any additional relevant 
studies. Citations were imported into RefWorks and 
all versions of citations lists were kept.19
Search strategy
To identify studies pertaining to our definition of 
medication reconciliation, a combination of medical 
subject heading terms and free-text search terms was 
developed by the review team in collaboration with a 
knowledge manager, a qualified librarian whose role 
includes searching and accessing published healthcare 
evidence. To identify studies describing medication 
reconciliation, the search terms ‘medication reconcili-
ation’, ‘medicines reconciliation’, ‘medication discrep-
ancy’, ‘medication error’, ‘medication adherence’ and 
‘medication counselling’ were combined. Search terms 
to identify studies at discharge from hospital included 
‘discharge’, ‘transition’ and ‘patient transfer’, and terms 
to identify pharmacists included ‘pharmacist’, ‘phar-
macy’ and ‘community pharmacy’. To identify studies 
set in the community rather than in hospital, several 
terms were combined, including ‘primary health care’, 
‘ambulatory care’, ‘family practice’, 'general practi-
tioner’ and ‘home care services’. No limit was placed 
on date of publication or language, and the search was 
adapted for each database. The final search syntax for 
Medline is available as an online supplementary file.
Eligibility criteria
For inclusion, studies had to fulfil the criteria in table 1. 
Following removal of duplicates, two reviewers inde-
pendently screened titles and abstracts of all citations 
(DM and MR). Full texts of all articles considered to be 
relevant were obtained and screened by two reviewers 
independently (DM and MR). Disagreements were 
resolved by discussion of full article content with the 
remaining reviewers.
Data extraction
Once the final set of studies was agreed, the lead 
reviewer (DM) extracted data from all studies. A 
second data extraction was completed independently 
by another member of the review team. A template 
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was created to allow collection of data relevant to the 
study questions. This was piloted with two studies and 
adapted following discussion of extracted data by the 
review team. The data extracted comprised details of 
the authors, publication, funding, aims, study design, 
inclusion and exclusion criteria, method of alloca-
tion to intervention or control group, sample sizes, 
participant characteristics, setting and details of the 
intervention, statistical techniques used, outcome 
data, and reported strengths, weaknesses and conclu-
sions.
Study details were tabulated to codify the study 
design, type of pharmacists, setting of intervention, 
number, timing and duration of contacts, and the 
description of collaboration with other team members. 
The outcome data that were extracted from each 
paper were rates of identification and resolution of 
discrepancies; rates of resolution of clinically relevant 
discrepancies; and measures of healthcare utilisation 
(rates of readmission, emergency department atten-
dance, GP attendance and measures of healthcare team 
member workload).
Risk of bias
The quality of each study and risk of bias were 
assessed independently by the two reviewers who 
performed the data extraction using the relevant Crit-
ical Appraisal Skills Programme (CASP) tools.20 These 
checklists facilitate a systematic approach to consid-
ering the presence or absence of certain elements 
within the study that may cause bias. Following 
completion of the CASP tool, the two reviewers 
discussed their findings for each study and graded the 
risk of bias as low, moderate or high. For example, one 
section asks: ‘Were controls recruited in an acceptable 
way?’ Selection bias may be introduced if participants 
are not randomised but could select allocation to the 
intervention or control group. Studies that recruited 
control groups in this manner would be deemed to 
have a higher risk of bias.
Data synthesis and analysis
Studies were grouped into RCTs, case–control studies 
and pre–post intervention studies. Other than for 
readmission rate, meta-analysis of outcome data could 
not be performed due to lack of data, heterogeneity 
of data and method of reporting outcome. To synthe-
sise discrepancy rate resolution and healthcare utilisa-
tion data, outcomes were compared narratively with 
the appraised risk of bias of each study defined by the 
weight given to findings.
Meta-analysis of readmission data was performed 
by calculating the Mantel-Haenszel risk ratio (RR) 
and 95% CIs. As interventions in the included studies 
varied, it was thought that there would not be one 
‘true’ effect size; therefore, a random-effects model was 
used within the Cochrane Review Manager (RevMan) 
V.5.3 software to synthesise results by constructing a 
forest plot.21 For studies that reported outcomes over 
different durations, the longest follow-up period for 
which all data were presented was used for analysis. 
Statistical heterogeneity was assessed by calculating τ2, 
χ2, I2 and P values. Publication bias was evaluated by 
construction and inspection of a funnel plot.
results
The electronic database search identified 3220 cita-
tions, with four more identified from the reference 
lists of included studies. After removal of duplicates, 
1610 citations remained. Following title and abstract 
review, 157 publications underwent full-text review. 
Fourteen studies met the inclusion criteria (figure 1).
Characteristics of included studies
Five included studies were RCTs, six were cohort 
studies, two were pre–post intervention studies and 
one was a quality improvement (QI) project that 
presented a run chart detailing pre–post intervention 
data (table 2). Two studies17 22 were deemed to have a 
low risk of bias. Although they were not blinded, both 
studies were RCTs and described robust randomisation 
Table 1 Study inclusion criteria
Characteristics Criteria for quantitative studies
Population Patients discharged from hospital to their permanent residence (home, residential unit or nursing home)
Intervention of interest Medicines reconciliation completed by a pharmacist based in the community 
Comparator Usual care processes for medication reconciliation
Outcome measure Discrepancy identification
Discrepancy categorisation
Healthcare usage (readmission, emergency department attendance, GP attendance)
Workload/efficiency measures—time to complete medicines reconciliation, effect on number of primary and secondary care 
appointments needed, and economic outcomes
Study design RCTs, cluster RCTs, quasi-RCTs, cluster quasi-RCTs, controlled pre–post intervention studies, interrupted-time-series, cohort 
studies (prospective or retrospective), case–control studies, uncontrolled pre–post intervention studies
Language No limitation
Publication date No limitation
GP, general practitioner or primary care physician; RCTs, randomised controlled trials.
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techniques to intervention or control group that other-
wise received similar care. All significant results were 
presented and treatment effects were presented in a 
precise manner. Eight studies were deemed to be of 
moderate risk of bias.23–30 RCTs in this group had less 
robust randomisation,24 25 had low numbers25 and 
were unable to account for all patients who entered 
the study (one24 reported a large dropout rate, and 
another25 had several patients who were unable to be 
reached by telephone for follow-up). Cohort studies 
in this group had robust methods to select controls 
and presented relevant data in a precise manner.26–29 
Four studies had a high risk of bias.31–34 These studies 
had less robust methods for assigning patients to 
intervention or control groups,31 32 or did not present 
all information on group allocation.33 34
Sample sizes ranged from 61 patients25 to 829.17 
Interventions varied by the patient group targeted, the 
setting within which it was completed, and the timing 
and number of contacts. Most studies targeted those 
considered at higher risk of readmission either through 
age17 22 30 32 or presence of a long-term condition.25 28 
Five studies evaluated medication reconciliation under-
taken by the pharmacist in the patient’s home,17 22 26–28 
whereas in three studies medication reconciliation was 
performed with the patient at a primary care clinic 
appointment.23 25 30 In one study, medication reconcil-
iation was completed by telephone,33 and in another, 
Figure 1 PRISMA flow diagram of selection of eligible studies. NICE, National Institute for Health and Care Excellence; PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses; AMED, Allied and Complementary Medicine Database; ERIC, Education Resources Information Center; 
CINAHL, Cumulative Index to Nursing and Allied Health Literature.
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reconciliation was performed either at a home visit for 
those with high risk of medication-related problems 
or by telephone for those with moderate risk.31 Two 
were set in nursing homes29 34 and one in a community 
pharmacy.24 In two studies medication reconciliation 
was completed in the absence of the patient.24 32
In seven studies patients were contacted 
once,25–29 33 34 in two studies twice,17 23 and in three 
studies the number of contacts varied dependent on 
patient preference and perceived need by pharma-
cists.22 30 31 Medication reconciliation was completed 
2 days before hospital discharge to the nursing home 
in one study.34 Six studies contacted the patient within 
the first week of discharge25 27 29–31 33 and four in 
the second week.17 22 23 26 In seven studies, pharma-
cists discussed outcomes of medication reconciliation 
with other team members such as the GP or nursing 
staff,22 25 26 30–33 whereas in four a written report was 
produced for other clinical staff.17 23 27 28
Effectiveness of identification, resolution and clinical relevance 
of discrepancies
The identification and resolution of discrepancies by 
pharmacists completing medication reconciliation was 
compared with usual care in four studies.24 25 28 32 In all 
four studies, rates of identification and resolution were 
greater in the intervention group (table 3).
Two studies compared the clinical relevance of 
resolved discrepancies between intervention and 
control groups and suggested that there was the poten-
tial for fewer adverse drug events after pharmacists 
had completed medication reconciliation (table 3).24 29 
Seven studies described the type of discrepancy found 
when pharmacists perform medication reconciliation 
(such as drug–drug interaction identified) but did not 
describe the clinical relevance.25–28 31 32 34
Healthcare utilisation
Healthcare utilisation was reported in 12 of the included 
studies. The different outcome measures reported 
included readmission rate at 1, 3, 6 and 12 months, 
emergency department attendance, and additional 
GP and secondary care consultations (table 3). Three 
studies reported a statistically significant reduction 
in readmission rate,25 31 33 whereas one reported 
an increase in readmission rate.17 Data from seven 
studies were included for meta-analysis. One study 
was excluded as only admissions related to myocar-
dial infarction or coronary revascularisation were 
included,23 another as the number of days hospitalised 
(rather than readmission rate) was reported28 and three 
more were excluded as they did not report numbers 
of patients readmitted.29 33 34 One of these33 reported 
a reduced readmission rate, whereas the others29 34 
reported no change. Two studies reported readmis-
sion rates over different time scales.22 27 In one study 
the longer time scale was used.27 The shorter time 
frame was used in the second study as the composite S
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readmission rate over the longer time frame was not 
clear. The pooled RR across all included studies (total 
number of patients=2336) was 0.91 (95% CI 0.66 to 
1.25), indicating no clear effect on readmission rate 
 (figure 2). There was a high degree of statistical heter-
ogeneity. As few studies were included, I2 is the most 
suitable statistic for assessing the impact of heteroge-
neity. An I2 value of 71% and P=0.002 were calcu-
lated, indicating high heterogeneity.35
Emergency department attendance rate was 
measured in three studies.25 26 34 No difference was 
observed between intervention and control groups in 
two studies,26 34 whereas in one a large reduction was 
found and this was a small RCT with a moderate risk 
of bias.
One study17 reported an increase in GP visits of 
43% in the intervention group, while another reported 
no significant difference in GP attendance.22 Two 
studies reported that pharmacist completing medica-
tion reconciliation had the potential to free up clin-
ical time for other healthcare team members. One 
reported that 2 hours of pharmacist time freed 3 hours 
of nursing time and 1 hour of physician time,34 and 
the other stated that planned and unplanned physician 
visits were reduced.28 Three studies reported the mean 
time taken to complete medication reconciliation by 
pharmacist. This varied from 1 hour 27 min to 3 hours 
51 min per patient.
discussion
The literature was systematically reviewed to evaluate 
the effectiveness of pharmacist-led medication recon-
ciliation performed in the community after hospital 
discharge. Pharmacists were more effective at identi-
fying and resolving discrepancies compared with the 
usual care process. Meta-analysis did not demonstrate 
a statically significant reduction in readmission rates, 
and the effect on emergency department attendance 
and workload of other healthcare team members was 
rarely measured and no consistent evidence of related 
benefit was found.
Comparison with previous literature
Previous systematic reviews also reported the ability of 
pharmacists to effectively identify and resolve discrep-
ancies in community14 and hospital settings.8 36 37 The 
clinical relevance of reduced discrepancy resolution 
has been questioned in studies set in the community as 
many discrepancies remained after interventions14 and 
the effect on patient outcomes was not consistent.15 
Several of our included studies derived their taxono-
mies of discrepancies empirically, which did not aid 
evaluation of clinical relevance.25–28 31 32 34 The lowest 
mean time to complete medication reconciliation 
reported in our included studies was 1 hour 27 min.22 
The time taken in usual care processes was never accu-
rately reported. Having more time to perform this task S
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may be the reason why more discrepancies are identi-
fied.
Unlike our study, a recent systematic review and 
meta-analysis of pharmacist-led medication reconcili-
ation in hospital performed at care transitions demon-
strated a reduction in healthcare use after discharge.7 
One possible explanation is that Mekonnen et al 
included studies with multiple intervention compo-
nents, including patient education, follow-up tele-
phone call, home visit, medication review, enhanced 
communication with primary care and the use of 
strategies to enhance adherence. Interventions in our 
systematic review included some of these components 
but excluded those describing a medication review 
and, as medication reconciliation was performed in 
the community, infrequently involved interventions 
to improve primary/secondary care communication. 
This may reflect the problem of varying definitions of 
medication reconciliation. The WHO defines medi-
cation reconciliation as ‘The formal process in which 
healthcare professionals partner with patients to ensure 
accurate and complete medication information transfer 
at interfaces of care’.1 Such a definition may legiti-
mately include all the aspects of interventions included 
by Mekonnen et al. The Joint Commission definition 
of ‘The process of comparing a patient’s medication 
orders to all of the medications that the patient has been 
taking’ is more precise and may not include such diverse 
activities.3 It may be that these additional components 
are important to influence health outcomes; however, 
recent systematic reviews of pharmacist-completed 
medication reviews in various settings have failed to 
show a benefit to patient outcomes.38 39
It is reported that roughly half of all discharge 
communications have been found to contain unin-
tended medications.40 Performing an accurate medi-
cation reconciliation using such a list is unlikely to 
improve patient outcomes as unintended medications 
will continue to be prescribed.17 However, even when 
medication is reconciled before discharge and patients 
followed up by pharmacists to improve adherence, 
clinically important medication errors and harm due 
to medication are not reduced.40
Implication for future policy and research
The lack of effect on patient outcomes raises the ques-
tion of what role the pharmacists should play post-
discharge. Patients are at a high risk of harm due to 
medication following discharge, and the involvement 
of pharmacists seems a logical step to reduce the risk 
of harm.41 Despite this, there is a paucity of high-
quality studies investigating pharmacist-led medica-
tion reconciliation postdischarge, and the few that do 
exist do not provide conclusive evidence of benefit. 
At present, pharmacist-completed medication recon-
ciliation postdischarge cannot be promoted to reduce 
harm and improve health outcome. Future research 
must do more than evaluate process measures such 
as discrepancy rate detection, and focus on evalu-
ating the clinical relevance of resolved discrepancies 
such as potential or actual adverse drug events. This 
may be more resource-intensive as clinical review of 
notes is required to make judgements on clinical rele-
vance.24 29 40 In addition, the development of an agreed 
taxonomy of discrepancies would be beneficial to aid 
process evaluation of such interventions and under-
standing of discrepancy relevance and why they occur.9
The lack of improvement in patient outcomes may 
be less important to policymakers and front-line clin-
ical teams if reduction in workload pressures improves 
performance in other areas of primary care such as 
face-to-face clinical care or administrative tasks such as 
laboratory test results handling. High levels of work-
load are perceived as a major safety concern in UK 
general practice, and one of the main policy drivers 
of pharmacist role development is to free clinical and 
administrative time for GPs.42 The effect of pharma-
cist-led medication reconciliation on these related 
systems has not been studied previously and further 
research is clearly needed.
If the pharmacist’s role in medication reconcilia-
tion postdischarge is to free clinical time, then imple-
mentation at scale will require significant financial 
and personnel resources.43 Future research should 
determine if these predicted efficiency savings exist 
and if other healthcare team members, such as phar-
macy technicians or existing primary care staff, can 
Figure 2 Forest plot of intervention effects on the proportion of patients with all-cause readmission. Diamond represents pooled estimate of relative risk 
calculated using Mantel-Haenszel (M-H) random effects model and 95% CIs. Squares represent study weighting, and horizontal bars represent 95% CI.
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perform medication reconciliation equally safely and 
improve cost-effectiveness.44 This research may iden-
tify if certain high-risk groups are more likely to derive 
benefit from pharmacy input postdischarge and what 
type of intervention has the most impact on medica-
tion safety (eg, reconciliation, review, adherence aids, 
health literacy aids).
Strengths and limitations
The search strategy included several relevant data-
bases, with no limitation placed on date of publication 
or language. Broader terms than medication recon-
ciliation were included in the search to incorporate 
studies reporting medication reconciliation as part of 
wider interventions. For example, although Holland et 
al describe their intervention as a medication review, 
we deemed it to be similar enough to our classification 
of medication reconciliation to be included. Screening 
for inclusion, data abstraction and quality appraisal 
were independently completed by two reviewers to 
enhance study rigour.
The study has several limitations. Some studies that 
would have been valuable in answering our questions 
may have been excluded as their focus of interven-
tion was not on medication reconciliation per se.45 
One study evaluated a community liaison pharma-
cist intervention but was based in hospital and so 
was excluded.46 Healthcare settings vary and findings 
from different countries may not be comparable. For 
example, studies were set in North American primary 
care services run by large organisations often with links 
to hospitals that may blur the lines between primary 
and secondary care.23 33 Others involved home care 
services that may not be present in other areas.28
The CASP tools used to assess bias and quality are 
designed for use in RCTs and cohort studies and were 
adapted to assess the quality of QI projects and pre–
post intervention studies. This led to these studies 
being treated as having a higher risk of bias. Several 
of the included studies were described as pilot proj-
ects25 32 or QI projects,27 33 34 and require more robust 
evaluation of their findings to determine if they are 
replicated at scale or in different settings. Included 
studies were generally of low to moderate quality and 
susceptible to bias, which means the positive outcomes 
reported in this systematic review must be treated with 
caution.
The meta-analysis of data from studies reporting 
readmission rates was limited to studies that reported 
similar outcomes; however, this approach may still be 
open to challenge. A high level of heterogeneity was 
identified with possible reasons including different 
study designs, settings, intervention components, 
outcome definitions and follow-up periods. This 
means that it is difficult to draw definitive conclusions 
from the meta-analysis other than to say that there is 
currently no firm evidence that readmission rate is 
reduced. Meta-analysis of other outcome measures 
was not possible due to heterogeneity of reported 
outcomes. For example, discrepancy identification 
rates were reported as the number of discrepancies 
per drug prescribed24; the number of patients in a 
study who had a discrepancy25; full or partial imple-
mentation of the patient plan32; and the number of 
discrepancies resolved.28 Despite the inclusion of a 
wide range of study type, publication bias may still 
influence results as demonstrated by the asymmetry of 
the funnel plot (figure 3). Of note, the smallest study 
showed the largest positive effect.25 It may be that 
smaller projects with less robust methods that did not 
show a positive effect were not published.
conclusions
This systematic review has shown that pharmacists can 
identify and resolve discrepancies while completing 
medication reconciliation after hospital discharge; 
however, the clinical relevance of these discrepan-
cies has rarely been reported. The evidence does not 
support a reduction in readmission rates and there 
is not consistent evidence that other measures of 
healthcare utilisation, such as emergency department 
attendance and GP appointments, are reduced. Future 
research in this area should compare the clinical rele-
vance of discrepancies identified and measure if this 
process reduces workload and thus frees clinical time 
in primary care.
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